Skip to main content
Premium Trial:

Request an Annual Quote

Scienion to Manufacture Protein Arrays for Protagen


Protagen announced this week that it has tapped Scienion to produce protein microarrays that it will use to validate panels of biomarkers that may later be used in clinical tests for multiple sclerosis and prostate cancer.

The number of arrays manufactured as part of the deal will be "more than one thousand," according to Dortmund, Germany-based Protagen.

Additionally, both companies plan to "jointly evaluate new platforms" for multiplex analysis and to "co-develop novel approaches up to proof-of-concept levels" as part of their partnership.

Protagen Chief Scientific Officer Peter Schulz-Knappe said that the firm partnered with Scienion to produce arrays for the "multicenter, international clinical validation studies of our multiplex diagnostic markers for the early detection of multiple sclerosis and the differential diagnosis of prostate cancer."

Schulz-Knappe said in a statement that Scienion's SciFlexArrayer instruments enable the manufacturing of protein microarray batches "each with more than 3,500 single proteins in highest quality and reproducibility."

CEO Stefan Müllner told BioArray News last month that the firm's tests are currently undergoing a multicenter clinical evaluation (BAN 3/29/2011).

Protagen is a new customer for Scienion, which operates from Dortmund as well as Berlin. Scienion CEO Holger Eickhoff said in a statement that the new deal "offers Scienion the possibility to perform feasibility studies close to the market and to demonstrate Scienion's capacity and efficiency to new customers from the diagnostics and pharma industry."

Scienion is keen to establish a place for itself in the market as a manufacturer of in vitro diagnostics. In February, the firm inked a deal with Euroimmun, a German medical diagnostics lab, to help it develop and manufacture new tests (BAN 2/22/2011).

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.